Literature DB >> 9417975

Cholinergic neurotransmission has different effects on cerebral glucose consumption and blood flow in young normals, aged normals, and Alzheimer's disease patients.

J Blin1, A Ivanoiu, A Coppens, A De Volder, D Labar, C Michel, E C Laterre.   

Abstract

Cerebral blood flow (CBF) and glucose consumption (GC) are both tracers of brain metabolic activity used to image the human brain in vivo. To know if both tracers reacted in the same manner when brain cholinergic neurotransmission was activated, CBF and GC were measured in young normals (YN), aged normals (AN), and Alzheimer's Disease patients (AD) using positron emission tomography (PET), H2 15O, and 18F-FDG. Each subject was studied twice, under placebo and physostigmine, in randomized order and blind fashion using the maximal tolerated dose of physostigmine individually determined. Under physostigmine CBF increased significantly (P = 0.0007) in posterior regions of the cerebral cortex and in the subcortical structures. Inversely, GC was decreased significantly in most regions. The largest decrease was seen in the prefrontal region of the cerebral cortex (P < 0.0001). Significant regional decreases were registered in all three groups of subjects, but were larger in AD than in controls. Looking at the absolute values of prefrontal cortex metabolism we found no correlation (r = 0.04) between the responses of CBF and GC. After normalization of the regional values for the mean we found a significant positive correlation between the responses of CBF and GC (r = 0.71, P < 0.0001). These findings suggest two components in the CBF response to physostigmine: one metabolic, depressive, and regional which follows the GC response; and one vascular, larger, diffuse, and opposite in direction to the metabolic component. These results have implications for the interpretation of CBF values as tracer of brain metabolic activity when brain cholinergic neurotransmission is manipulated. Copyright 1997 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9417975     DOI: 10.1006/nimg.1997.0296

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  10 in total

Review 1.  Cholinergic modulation of cognition: insights from human pharmacological functional neuroimaging.

Authors:  Paul Bentley; Jon Driver; Raymond J Dolan
Journal:  Prog Neurobiol       Date:  2011-06-17       Impact factor: 11.685

Review 2.  Inflammation and Alzheimer's disease.

Authors:  H Akiyama; S Barger; S Barnum; B Bradt; J Bauer; G M Cole; N R Cooper; P Eikelenboom; M Emmerling; B L Fiebich; C E Finch; S Frautschy; W S Griffin; H Hampel; M Hull; G Landreth; L Lue; R Mrak; I R Mackenzie; P L McGeer; M K O'Banion; J Pachter; G Pasinetti; C Plata-Salaman; J Rogers; R Rydel; Y Shen; W Streit; R Strohmeyer; I Tooyoma; F L Van Muiswinkel; R Veerhuis; D Walker; S Webster; B Wegrzyniak; G Wenk; T Wyss-Coray
Journal:  Neurobiol Aging       Date:  2000 May-Jun       Impact factor: 4.673

3.  Altered neural cholinergic receptor systems in cocaine-addicted subjects.

Authors:  Bryon Adinoff; Michael D Devous; Mark J Williams; Susan E Best; Thomas S Harris; Abu Minhajuddin; Tanya Zielinski; Munro Cullum
Journal:  Neuropsychopharmacology       Date:  2010-03-10       Impact factor: 7.853

4.  A pilot study evaluating the efficacy and safety of rivastigmine in patients with mixed dementia.

Authors:  Steven G Potkin; Gus Alva; Ibrahim Gunay; Barbara Koumaras; Michael Chen; Dario Mirski
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 5.  Imaging brain signal transduction and metabolism via arachidonic and docosahexaenoic acid in animals and humans.

Authors:  Mireille Basselin; Epolia Ramadan; Stanley I Rapoport
Journal:  Brain Res Bull       Date:  2011-12-09       Impact factor: 4.077

6.  Adverse Vascular Risk Relates to Cerebrospinal Fluid Biomarker Evidence of Axonal Injury in the Presence of Alzheimer's Disease Pathology.

Authors:  Katie E Osborn; Jonathan M Alverio; Logan Dumitrescu; Kimberly R Pechman; Katherine A Gifford; Timothy J Hohman; Kaj Blennow; Henrik Zetterberg; Angela L Jefferson
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 7.  Cerebral Hypoperfusion and the Energy Deficit in Alzheimer's Disease.

Authors:  Seth Love; J Scott Miners
Journal:  Brain Pathol       Date:  2016-09       Impact factor: 6.508

8.  Embelin Improves the Spatial Memory and Hippocampal Long-Term Potentiation in a Rat Model of Chronic Cerebral Hypoperfusion.

Authors:  Saatheeyavaane Bhuvanendran; Siti Najmi Syuhadaa Bakar; Yatinesh Kumari; Iekhsan Othman; Mohd Farooq Shaikh; Zurina Hassan
Journal:  Sci Rep       Date:  2019-10-10       Impact factor: 4.379

9.  Scopolamine-induced "cholinergic stress test" in the elderly.

Authors:  Gustavo C Román; Robert E Jackson; E Mariana Longoria; Ronald E Fisher
Journal:  Front Pharmacol       Date:  2014-08-13       Impact factor: 5.810

Review 10.  Vascular dementia and the cholinergic pathways.

Authors:  Eliasz Engelhardt; Denise Madeira Moreira; Jerson Laks
Journal:  Dement Neuropsychol       Date:  2007 Jan-Mar
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.